References
- Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52
- Lutton JD, Winston R, Rodman TC. Multiple sclerosis: etiological mechanisms and future directions. Exp Biol Med (Maywood) 2004;229:12-20
- Naci H, Fleurence R, Birt J, Duhig A. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics 2010;28:363-79
- Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm 2010;16:703-12
- Naci H, Fleurence R, Birt J, Duhig A. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. J Med Econ 2010;13:78-89
- Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009;65:239-48
- Castro-Borrero W, Graves D, Frohman TC, et al. Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord 2012;5:205-20
- Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. CNS Drugs 2004;18:561-74
- Tappenden P, McCabe C, Chilcott J, et al. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health 2009;12:657-65
- Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology 2011;77:355-63
- Carroll CA, Fairman KA, Lage MJ. Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data. BMC Health Serv Res 2014;14:1
- Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ 2013;16:639-47
- Schafer JA, Gunderson BW, Gleason PP. Price increases and new drugs drive increased expenditures for multiple sclerosis. J Manag Care Pharm 2010;16:713-17
- Kunze AM, Gunderson BW, Gleason PP, et al. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs – pharmacy and medical benefit spending from 2004 through 2007. J Manag Care Pharm 2007;13:799-806
- Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52
- Sipkoff M. Higher copayments and deductibles delay medical care, a common problem for Americans. Manag Care 2010;19:46-9
- Haren MC, McConnell K, Shinn AF. Increased patient cost-sharing, weak US economy, and poor health habits: implications for employers and insurers. Am Health Drug Benefits 2009;2:134-41
- Regopoulos LE, Trude S. Employers shift rising health care costs to workers: no long-term solution in sight. Issue Brief Cent Stud Health Syst Change 2004;83:1-4
- Gencarelli DM. Average wholesale price for prescription drugs: is there a more appropriate pricing mechanism? NHPF Issue Brief 2002;775:1-19
- Curtiss FR, Lettrich P, Fairman KA. What is the price benchmark to replace average wholesale price (AWP)? J Manag Care Pharm 2010;16:492-501
- Gencarelli DM. One pill, many prices: variation in prescription drug prices in selected government programs. Issue Brief George Wash Univ Natl Health Policy Forum 2005;807:1-20
- Glied S, Haninger K. Medicare Part B Reimbursement of Prescription Drugs. ASPE. Available at: https://aspe.hhs.gov/report/medicare-part-b-reimbursement-prescription-drugs [Last accessed 15 June 2015]
- Centers for Medicare & Medicaid Services. Available at: http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Pharmacy-Pricing.html [Last accessed 15 June 2015]
- Red Book Online. Greenwood Village, CO: Truven Health Analytics Inc. 2015
- US Food and Drug Administration. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [Last accessed 5 January 2015]
- Hartung DM, Bourdette DN, Ahmed SM, Whitham RH. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail? Neurology 2015;84:2185-92